anti-ACE2 (human), mAb (AC384)
1: Human ACE2 Fc-fusion protein.
2: Human ACE2 (Ecto domain) (FLAG®-tagged).
3: HepG2 cell lysate.
4: Other Fc-fusion (hGITR-Fc) proteins (negative control).
|Synonyms||SARS Receptor; Angiotensin-converting Enzyme 2; ACEH; Metalloprotease MPROT15; SARS-CoV-2 Receptor|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant human ACE2.|
ELISA: (direct or indirect: 1:2'000-1:10'000)
Recognizes human ACE2.
|Purity Detail||Protein G-affinity purified.|
|Formulation||Liquid. 0.2μm-filtered solution in PBS, pH 7.4.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
Angiotensin-converting enzyme2 (ACE2) is an ectoenzyme (carboxypeptidase) with an extracellular catalytic domain that predominantly localizes at the plasma membrane and is thereby able to hydrolyze circulating peptides. ACE2 has approximately 42% sequence identity with ACE, and its cytoplasmic and transmembrane domains show 48% homology to the protein collectrin that plays a critical role in the amino acid absorption of the kidney. ACE2 converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. ACE2 is involved in the regulation of systemic blood pressure and has direct effects on cardiac functions. It is expressed predominantly in endothelial cells of the lung, gut, heart and kidney. ACE2 together with the protease TMPRSS2 acts as a functional receptor for SARS coronavirus as well as for the new highly pathogenic coronavirus, 2019-nCoV/SARS-CoV-2, which is cause for pneumonia COVID-19.
- Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2): K. Liao, et al.; J. Immunol. Meth. 389, 52 (2013)
- Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications: VB. Patel, et al.; Clin. Sci. 126, 471 (2014)
- Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro: F. Curreli, et al.; mBio 11, e02451 (2020)
- Relevance of VEGF and CD147 in different SARS-CoV-2 positive digestive tracts characterized by thrombotic damage: D. Bortolotti, et al.; FASEB J. 35, e21969 (2021)